Article Figures & Data
Figures
- FIGURE 1.
Pretherapy (A) and posttherapy (B) CT images of liver of patient 7 show that multiple large, hypodense lesions seen at baseline were significantly smaller on posttherapy CT.
- FIGURE 2.
Pretherapy (A) and posttherapy (B) CT images of liver of patient 10 show that multiple large, hypodense lesions seen at baseline did not change significantly after therapy.
Tables
Favorable response criteria* Unfavorable response criteria† •Improvement of at least 1 major symptom without worsening of others •Worsening of any symptom •Improvement of Karnofsky score by 10 points or more •Worsening of Karnofsky score by 10 points or more •Weight gain of 5% or more •Weight loss of more than 5% •Improvement of health state score by at least 10 points •Worsening of health state score by at least 10 points Patient no. Tumor type Weight (kg) Health state score Karnofsky score Fatigue Abdominal pain Diarrhea N/V Flushing Overall clinical response Before After Before After Before After 1 Carcinoid 56.3 54.6 80 75 90 90 Unchanged Improved N/A N/A N/A −1 2 Islet cell 56.5 62.6 80 90 80 90 Improved N/A N/A Improved N/A 4 3 Carcinoid 70 78.1 80 80 90 100 Improved N/A N/A N/A N/A 3 4 Carcinoid 62 62.9 60 85 80 90 Improved Improved N/A Improved Unchanged 3 5 Islet cell 64.5 57 65 50 80 70 Worsened Unchanged N/A Unchanged N/A −4 6 Glucagonoma 88 93.5 80 73 90 90 Improved Improved Unchanged Unchanged N/A 2 7 Neuroendo/ unknown origin 87.8 97 62 90 80 100 Improved N/A Improved Improved N/A 4 8 Carcinoid 78 79 70 75 70 80 Improved Unchanged N/A Unchanged N/A 2 9 Carcinoid 117 113 80 75 90 90 Unchanged Improved Improved N/A N/A 1 10 Carcinoid 66 69.4 40 90 90 90 Improved Improved Unchanged N/A Improved 3 11 Carcinoid 104 107 80 85 90 100 Improved N/A N/A N/A Improved 2 12 Carcinoid 64 64 82 70 90 90 Unchanged Improved Unchanged N/A Improved 0 13 Carcinoid 73 74.3 70 80 90 90 Unchanged Improved Improved N/A Improved 2 14 Carcinoid 58 54 70 80 90 90 Improved Improved Unchanged Improved N/A 1 15 Carcinoid 84 84 75 80 90 95 Improved N/A N/A N/A Improved 1 16 Carcinoid 73 73 50 70 70 80 Improved N/A N/A N/A Improved 3 17 Carcinoid 115 120 50 40 80 70 Unchanged N/A Worsened N/A Unchanged −3 18 Carcinoid 66 68 70 98 90 90 Unchanged N/A N/A N/A Improved 2 19 Carcinoid 66 62 60 75 80 90 Unchanged N/A Improved N/A 2 20 Carcinoid 106 105 45 60 80 80 N/A N/A Improved N/A Improved 2 21 Carcinoid 59 59 75 76 80 90 Improved Improved Improved N/A Improved 2 N/V = nausea/vomiting; N/A = not applicable; neuroendo = neuroendocrine tumor.
Patient no. Octreotide dose (mg) Clinical response Before therapy After therapy 1 1,200 100 S 2 300 900 I 3 0 0 I 4 300 200 I 5 100 0 P 6 300 150 I 7 600 600 I 8 1,200 1,200 I 9 600 600 S 10 600 300 I 11 300 0 I 12 6,000 2,100 S 13 600 450 I 14 600 100 I 15 600 600 S 16 1,600 1,350 I 17 1,500 1,500 P 18 600 300 I 19 400 300 I 20 600–900 600 I 21 800 600 I S = stable; I = improved; P = progression.
In this issue
Jump to section
Related Articles
Cited By...
- Management of neuroendocrine tumors
- Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors
- Molecular radiotherapy
- Radiopeptide Imaging and Therapy in the United States
- Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
- 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
- Treatment of Metastatic Carcinoid Tumors With Radiolabeled Biologic Molecules
- Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor-Positive Pediatric Tumors
- Potential Increased Tumor-Dose Delivery with Combined 131I-MIBG and 90Y-DOTATOC Treatment in Neuroendocrine Tumors: A Theoretic Model
- Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
- Evaluation of [99mTc/EDDA/HYNIC0]Octreotide Derivatives Compared with [111In-DOTA0,Tyr3, Thr8]Octreotide and [111In-DTPA0]Octreotide: Does Tumor or Pancreas Uptake Correlate with the Rate of Internalization?
- Preclinical Evaluation of New and Highly Potent Analogues of Octreotide for Predictive Imaging and Targeted Radiotherapy
- 68Ga-Labeled Peptides in Tumor Imaging
- Combination Radionuclide Therapy Using 177Lu- and 90Y-Labeled Somatostatin Analogs
- Patient-Specific Dosimetry in Predicting Renal Toxicity with 90Y-DOTATOC: Relevance of Kidney Volume and Dose Rate in Finding a Dose-Effect Relationship
- Overview of Results of Peptide Receptor Radionuclide Therapy with 3 Radiolabeled Somatostatin Analogs